The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs
- 87 Downloads
The study aimed to define the effects of M. haemolytica and a single oral dose of albendazole on the single-dose pharmacokinetics of marbofloxacin in lambs. The pharmacokinetic–pharmacodynamic integration of marbofloxacin was applied to describe a 3 mg/kg intramuscular dose in lambs. The 6 healthy and 12 naturally infected with M. haemolytica lambs (Akkaraman, males weighing 10–15 kg and aged 2–3 months) were used in this study. In the marbofloxacin group, 6 healthy lambs received marbofloxacin. In the albendazole group after 2 weeks washout period, the same animals received marbofloxacin on 1 h after albendazole. In the diseased marbofloxacin group, 6 lambs naturally infected with M. haemolytica received marbofloxacin. In the diseased albendazole group, 6 lambs naturally infected with M. haemolytica received marbofloxacin on 1 h after albendazole. The marbofloxacin and albendazole were administered each as a single dose of 3 mg/kg intramuscular and 7.5 mg/kg oral, respectively, in the respective groups. Plasma concentration of marbofloxacin was measured with HPLC-UV and pharmacokinetic parameters were analyzed by non-compartmental model. Albendazole did not change the pharmacokinetic profiles of marbofloxacin in healthy and diseased lambs. However, M. haemolytica affected the pharmacokinetics of marbofloxacin in diseased lambs, AUC0–24/MIC90 ratio was not found to be higher than 125, but Cmax/MIC90 ratios was found to be higher than 10 for an MIC value of 0.25 μg/mL in all groups. The marbofloxacin dose described in this study may not be effective for the treatment of infections due to M. haemolytica in lambs, with MIC ≤ 0.25 μg/mL.
KeywordsAlbendazole Lamb Mannheimia haemolytica Marbofloxacin Pharmacokinetics
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Thanks are due to Ceva Animal Health Inc., Turkey, for supplying MB pure substance. Abstract presented form at the WVAC 2018 - 34th World Veterinary Association Congress Barcelona, Spain, May 2018.
Compliance with ethical standards
The authors declare that they have no conflict of interest.
Ethics approval and consent to participate
Animal experiments were carried out under the approval protocol of the Ethics Committee of the Dicle University Animal Experiments (Diyarbakir, Turkey, permit No 28/2014), which is in adherence with the Rules for the Working Procedures and Principles of the Ethical Committees of Animal Experiments and Animal Protection Act.
- Alomar, M.J., 2014. Factors affecting the development of adverse drug reactions (Review article)Google Scholar
- Altan, F., Corum, O., Corum, D.D., Atik, O. and Uney, K., 2018. Pharmacokinetics and bioavailability of marbofloxacin in lambs following administration of intravenous, intramuscular and subcutaneous Small Ruminant Research, 159, 5–10Google Scholar
- Ambrose, P.G., Bhavnani, S.M., Rubino, C.M., Louie, A., Gumbo, T., Forrest, A. and Drusano, G.L., 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 44, 79–86Google Scholar
- Balikci, E., Kizil, O., Karapinar, T., Karahan, M., Ozdemir, H. and Dabak, M., 2008. Efficacy of marbofloxacin for naturally occurring contagious caprine pleuropneumonia Small Ruminant Research, 77, 75–79Google Scholar
- Bapiro, T.E., Andersson, T.B., Otter, C., Hasler, J.A. and Masimirembwa, C.M., 2002. Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. European Journal of Clinical Pharmacology, 58, 537–542PubMedGoogle Scholar
- Bell, S., 2008. Respiratory disease in sheep: 1. Differential diagnosis and epidemiology. In Practice, 30, 200–207Google Scholar
- Calbo, E., Alsina, M., Rodríguez-Carballeira, M., Lite, J. and Garau, J., 2008. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: Effects of treatment with a β-lactam versus a fluoroquinolone Antimicrobial Agents and Chemotherapy, 52, 2395–2402PubMedPubMedCentralGoogle Scholar
- Drusano, G.L., 2007. Pharmacokinetics and Pharmacodynamics of Antimicrobials Clinical Infectious Diseases, 45, 89–95Google Scholar
- Elmas, M., Yazar, E., Uney, K., Er Karabacak A., and Traş, B., 2008. Pharmacokinetics of enrofloxacin and flunixin meglumine and interactions between both drugs after intravenous co-administration in healthy and endotoxaemic rabbits Veterinary Journal, 177, 418–424Google Scholar
- Giacomini, K.M., Huang, S.-M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L.R., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K.M., Hoffmaster, K.A., Ishikawa, T., Keppler, D., Kim, R.B., Lee, C.A., Niemi, M., Polli, J.W., Sugiyama, Y., Swaan, P.W., Ware, J.A., Wright, S.H., Wah Yee, S., Zamek-Gliszczynski, M.J. and Zhang, L., 2010. Membrane transporters in drug development Nature Reviews Drug Discovery, 9, 215–236PubMedGoogle Scholar
- MacFaddin, J., 2000. Biochemical Tests for the Identification of Aerobic Bacteria Clinical Microbiology Procedures Handbook, 3rd Edition, 503–642Google Scholar
- Morgan, E.T., 2009. Impact of Infectious and Inflammatory Disease on Cytochrome P450 – Mediated Drug Metabolism and Pharmacokinetics Nature, 85, 434–438Google Scholar
- Palleria, C., Di Paolo, A., Giofrè, C., Caglioti, C., Leuzzi, G., Siniscalchi, A., De Sarro, G. and Gallelli, L., 2013. Pharmacokinetic drug-drug interaction and their implication in clinical managementGoogle Scholar
- Pomorska-Mól, M. and Pejsak, Z., 2015. Effect of therapeutic doses of enrofloxacin on circulating lymphocyte subpopulations in pigs Bulletin of the Veterinary Institute in Pulawy, 59(2), 287–293Google Scholar
- Potter, T., Illambas, J., Pelligand, L., Rycroft, A. and Lees, P., 2013. Pharmacokinetic and pharmacodynamic integration and modelling of marbofloxacin in calves for Mannheimia haemolytica and Pasteurella multocida Veterinary Journal, 195, 53–58Google Scholar
- Real, R., Egido, E., Pérez, M., González-Lobato, L., Barrera, B., Prieto, J.G., Alvarez, A.I. and Merino, G., 2011. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin. Journal of veterinary pharmacology and therapeutics, 34, 313–321PubMedGoogle Scholar
- Skoufos, J., Christodoulopoulos, G., Fragkou, I.A., Tzora, A., Gougoulis, D.A., Orfanou, D.C., Tsiolaki, K. and Fthenakis, G.C., 2007. Efficacy of marbofloxacin against respiratory infections of lambs Small Ruminant Research, 71, 304–309Google Scholar
- Voigt, K., Brügmann, M., Huber, K., Dewar, P., Cousens, C., Hall, M., Sharp, J.M. and Ganter, M., 2007. PCR examination of bronchoalveolar lavage samples is a useful tool in pre-clinical diagnosis of ovine pulmonary adenocarcinoma (Jaagsiekte) Research in Veterinary Science, 83, 419–427PubMedGoogle Scholar